Schlusskurs
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
0.41 EUR | +22.02% | -89.27% | -85.86% |
Kurzporträt
Die Gruppe hat ein Produkt in der klinischen Entwicklung der Phase II/III (Glenzocimab).
Mitarbeiterzahl: 29
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Gilles Avenard
FOU | Founder | - | 26.11.13 |
Eric Cohen
DFI | Director of Finance/CFO | - | - |
Adeline Meilhoc
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 01.11.18 | |
Aymeric Humblot
ADM | Chief Administrative Officer | - | - |
Sophie Binay
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yannick Plétan
CTO | Chief Tech/Sci/R&D Officer | - | 20.12.17 |
James Stearns
PRN | Corporate Officer/Principal | - | - |
Jessica Jami
LAW | General Counsel | - | 01.11.19 |
Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Gilles Avenard
FOU | Founder | - | 26.11.13 |
Catherine Boule
BRD | Director/Board Member | - | - |
Alain Munoz
CHM | Chairman | 75 | 15.06.21 |
Alain Parthoens
BRD | Director/Board Member | 64 | 24.10.18 |
Rinaldo del Bono
BRD | Director/Board Member | - | - |
Guy Heynen
BRD | Director/Board Member | - | - |
Patricia Zilliox
BRD | Director/Board Member | - | 26.01.23 |
Corporate Officer/Principal | - | - | |
Leila Nicolas
BRD | Director/Board Member | - | - |
Director/Board Member | - | - |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 12 338 781 | 12 338 781 ( 100,00 %) | 0 | 100,00 % |
Unternehmenskontakt
Acticor Biotech SAS
Bâtiment Inserm U1148 Hôpital Bichat
75877, Paris
+33 6 76 23 38 13
http://www.acticor-biotech.comSektor
Verlauf des Gewinns je Aktie
Jahresgewinne - Abweichungsrate
% 1. Jan. | Kap. | |
---|---|---|
-85.86% | 5.77 Mio. | |
-3.03% | 102 Mrd. | |
+1.66% | 96.29 Mrd. | |
+2.13% | 22.18 Mrd. | |
-15.38% | 21.2 Mrd. | |
-9.21% | 18.31 Mrd. | |
-39.98% | 17.38 Mrd. | |
-15.38% | 16.36 Mrd. | |
+5.04% | 13.97 Mrd. | |
+32.65% | 12.17 Mrd. |
- Börse
- Aktien
- ALACT Aktie
- Unternehmen Acticor Biotech SAS